Lupin Secures FDA Approval for Phytonadione Injectable Emulsion

The newly approved 1 mg/0.5 mL syringe is classified as bioequivalent to the reference product marketed by International Medication Systems, Limited. This regulatory clearance allows Lupin to enter a market segment that recorded estimated annual sales of 52.3 million dollars in the United States, according to August 2026 data from IQVIA.

Lupin, which maintains a significant footprint across global markets, continues to leverage its 15 manufacturing facilities and six research centers to bolster its portfolio of generics and specialty medicines. The company currently employs over 26,000 people and operates extensively across the cardiovascular, respiratory, and diabetes sectors. This approval reinforces the firm's standing in the U.S. medical ecosystem while providing patients with an alternative for managing blood clotting disorders.